Advanced Solution has announced an exclusive distribution collaboration with Royal Wound X to commercialise the chorion-free amniotic allograft, AbioMend X Plus, for wound care.
The single-layer solution is designed to enhance wound healing and tissue regeneration.
Go deeper with GlobalData
It is also tailored via a crosslinking process that claims to offer structural integrity against non-crosslinked grafts.
This process enables AbioMend X Plus to be beneficial for long-term wound coverage, setting it apart from rapidly degrading non-crosslinked amniotic membranes, as stated by the company.
According to Advanced Solution, it ensures that the membrane “retains” the required growth factors while minimising the quick degradation or host rejection risk.
The applications for AbioMend X Plus are diverse, covering chronic wounds such as diabetic and pressure ulcers, burns, trauma wounds, and surgical wounds, as well as procedures in ophthalmology and orthopaedics.
Advanced Solution’s founder and CEO Luke Etter, along with co-owner and chief operating officer Jonathan Sharp, has been instrumental in making the company a distributor of biologics and medical technology solutions across the US.
The company noted that as an exclusive distributor, it is committed to ensuring that AbioMend X Plus is accessible via a national network of healthcare institutions and professionals.
Advanced Solution chief commercial officer Taylor Saffire said: “This partnership is a major milestone in our mission to deliver the most effective and innovative solutions in wound care.
“We’ve worked closely with Royal Wound X over the years, and we’re excited to bring AbioMend X Plus to providers and patients who need it most.”
